Related Experiment Video
Updated: Mar 1, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Elevated Serum Interleukin 6 Is Associated With High Risk of First Non-bleeding Decompensation in Patients With
Yuji Kita1, Yuji Ikeda1, Hiroki Nago1
1Department of Gastroenterology and Hepatology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Background/Aim:
The transition from compensated to decompensated cirrhosis indicates a poor prognosis, and decompensated symptoms are subclassified as bleeding and non-bleeding. This study aimed to investigate the association between serum systemic inflammation marker levels and the development of the first bleeding and non-bleeding decompensation in patients with compensated cirrhosis.
Patients And Methods:
This retrospective study included 214 patients with compensated liver cirrhosis. The baseline serum C-reactive protein, interleukin 6, procalcitonin, and serum amyloid A protein levels were measured. Factors associated with the first decompensation were assessed using the Cox proportional hazards model. The probability of first decompensation was evaluated using Kaplan-Meier analysis and the log-rank test.
Results:
In the study cohort, 167 (78%) patients showed elevation of one or more systemic inflammation markers. During a median follow-up of 3.6 years, 28 and 35 patients developed first bleeding and non-bleeding decompensation, respectively. The multivariate Cox proportional hazards model identified that nonviral etiology and low platelet count were significantly associated with bleeding decompensation and nonviral etiology, albumin-bilirubin grade, and serum interleukin 6 level with non-bleeding decompensation. Kaplan-Meier analyses showed that patients with high serum interleukin 6 levels (≥10 pg/ml) showed significantly higher probability of first non-bleeding decompensation than those with low serum interleukin 6 levels, but probability of bleeding decompensation was not different between them.
Conclusion:
Serum pro-inflammatory cytokine interleukin 6 predicts the risk of first non-bleeding decompensation but not bleeding decompensation in patients with compensated cirrhosis.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Esophageal Varices-I: Introduction
Nephrotic Syndrome I : Introduction

